06/26/2023

Roswell Park Comprehensive Cancer Center

Researchers from Tempus partnered with the Roswell Park Comprehensive Cancer Center to study aberrations in patients with metastatic non-small cell lung cancer. 

FGFR fusions represent a potential mechanism of resistance to EGFR inhibitors. This study characterizes the prevalence of these alterations and the landscape of co-mutations that may be of high interest to drug developers targeting FGFR fusions.

This study was presented at the Targeted Therapies of Lung Cancer Meeting in February 2023.

Related Content

View more